Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04231318 · ClinicalTrials.gov registry record · Phase 3
Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain
A Phase 3 study, sponsored by Anika Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 231
- Enrollment target
NCT04231318 is a Phase 3 study that has completed, run by Anika Therapeutics. The registered enrollment target is 231 participants.
The verdict
NCT04231318, a Phase 3 study, has completed, sponsored by Anika Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 231 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, parallel group, placebo controlled trial to compare the safety and effectiveness of a single injection of Cingal® to a single injection of Triamcinolone Hexacetonide (TH) to achieve pain relief and other symptoms of osteoarthritis of the knee.
Interventions
- DRUG Placebo
- DRUG Cingal
- DRUG Triamcinolone Hexacetonide (TH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2022-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04231318
The ClinicalTrials.gov registry entry for NCT04231318 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anika Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04231318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04231318 about?
NCT04231318 is a clinical study titled "Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain". This is a multi-center, randomized, double-blind, parallel group, placebo controlled trial to compare the safety and effectiveness of a single injection of Cingal® to a single injection of Triamcinolone Hexacetonide (TH) to achieve pain relief and other symptoms of osteoarthritis of the knee.
What is the current status of trial NCT04231318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 231 participants. The study started on 2020-09-11. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT04231318?
The interventions under investigation include: Placebo (DRUG), Cingal (DRUG), Triamcinolone Hexacetonide (TH) (DRUG).
Who is sponsoring clinical trial NCT04231318?
This trial is sponsored by Anika Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.